Get the Stockscreener App
1.70
0.59%
0.01
After Hours:
1.72
0.02
+1.18%
Aprea Therapeutics Inc stock is traded at $1.70, with a volume of 13,629.
It is up +0.59% in the last 24 hours and down -1.73% over the past month.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
See More
Previous Close:
$1.69
Open:
$1.69
24h Volume:
13,629
Relative Volume:
0.28
Market Cap:
$9.40M
Revenue:
-
Net Income/Loss:
$-14.29M
P/E Ratio:
-0.4261
EPS:
-3.99
Net Cash Flow:
$-12.27M
1W Performance:
-5.03%
1M Performance:
-1.73%
6M Performance:
-50.44%
1Y Performance:
-47.20%
1-Day Range:
$1.675
$1.73
1-Week Range:
$1.55
$1.82
52-Week Range:
$1.412
$5.01
Aprea Therapeutics Inc Stock (APRE) Company Profile
Name
Aprea Therapeutics Inc
Sector
Industry
Phone
215-948-4119
Address
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Compare APRE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
1.70 | 9.40M | 0 | -14.29M | -12.27M | -3.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Jun-22-20 | Initiated | H.C. Wainwright | Neutral |
| Apr-21-20 | Initiated | Robert W. Baird | Outperform |
| Oct-28-19 | Initiated | JP Morgan | Neutral |
| Oct-28-19 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-28-19 | Initiated | RBC Capital Mkts | Outperform |
View All
Aprea Therapeutics Inc Stock (APRE) Latest News
How hedge fund analytics apply to Aprea Therapeutics Inc. stockMulti-Year Investment Performance Summary Report - Newser
Aprea Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Aprea Therapeutics, Inc. SEC 10-Q Report - TradingView
Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update - The Manila Times
Analyzing drawdowns of Aprea Therapeutics Inc. with statistical toolsFree Market Momentum and Signal Alerts - Newser
Aprea Therapeutics Inc. stock retracement – recovery analysisStock Market Watch with Smart Filters - Newser
How to forecast Aprea Therapeutics Inc. trends using time seriesBreakout Screener With Alert Based Timing - Newser
Why Aprea Therapeutics Inc. stock attracts strong analyst attentionInsider Strategy for High Conviction Picks - Newser
Published on: 2025-08-11 23:58:33 - Newser
How Aprea Therapeutics Inc. stock performs during market volatilityBuy and Hold Return Summary with Charts - Newser
How to interpret RSI for Aprea Therapeutics Inc. stockFree Daily Stock Market Swing Alerts - Newser
What’s next for Aprea Therapeutics Inc. stock priceChart Scanner for Swing Trade Timing - Newser
Long term hold vs stop loss in Aprea Therapeutics Inc.Free Weekly Return Pick Forecast Reports - Newser
Is Aprea Therapeutics Inc. meeting your algorithmic filter criteriaMarket Opportunity Tracker for Swing Traders - Newser
Signal strength of Aprea Therapeutics Inc. stock in tech scannersExit Strategy Guide With Risk Control Plan - Newser
Is Aprea Therapeutics Inc. forming a bottoming baseTechnical Trend Forecast for Investors - Newser
Can you recover from losses in Aprea Therapeutics Inc.Rapid Trade Forecast Based on Indicators - Newser
Is Aprea Therapeutics Inc. Stock Overbought or Oversold RSI Indicator AnalysisFree Real Time Trade Opportunity Alerts - Newser
Buy Signal for Aprea Therapeutics Inc. Stock Key Technical Indicators to WatchMomentum Screener with Buy and Sell Areas - Newser
Is it too late to sell Aprea Therapeutics Inc.Daily Pattern Analysis with Return Forecast - Newser
Combining price and volume data for Aprea Therapeutics Inc.Predictable Income Summary for Long-Term Trades - Newser
Multi asset correlation models including Aprea Therapeutics Inc.Entry Confirmation Based on Volatility Analysis - Newser
What candlestick patterns are forming on Aprea Therapeutics Inc.Free Early Entry Tips With Low Risk Zone - Newser
Aprea Therapeutics (APRE) to Release Quarterly Earnings on Monday - Defense World
Strategies to average down on Aprea Therapeutics Inc.Swing Reversal Forecast Based on Patterns - Newser
Aprea Therapeutics APRE 2025Q2 Earnings Preview Upside Potential Amid Breakthrough Therapy Designation - AInvest
Key resistance and support levels for Aprea Therapeutics Inc.Buy Opportunity Forecast for Fast Traders - Newser
Applying Wyckoff theory to Aprea Therapeutics Inc. stockTrading Opportunities Forecast by AI Insight - Newser
Trend analysis for Aprea Therapeutics Inc. this week3-Day Market Movement Forecast Analysis - Newser
Quantitative breakdown of Aprea Therapeutics Inc. recent moveAutomated AI Forecast with Trading Alerts - Newser
Real time social sentiment graph for Aprea Therapeutics Inc.Risk Aware Swing Trade Analysis Insights - Newser
Key metrics from Aprea Therapeutics Inc.’s quarterly dataWeekly Chart Watchlist with Trade Guidance - Newser
Aprea Therapeutics Inc Stock (APRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aprea Therapeutics Inc Stock (APRE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Duey Marc | Director |
Oct 18 '24 |
Sale |
4.58 |
6,462 |
29,583 |
233,651 |
| Gilad Oren | President/CEO |
Oct 23 '24 |
Buy |
3.92 |
500 |
1,958 |
333,395 |
| Duey Marc | Director |
Oct 16 '24 |
Buy |
4.39 |
30,000 |
131,700 |
240,113 |
| Gilad Oren | President/CEO |
Oct 15 '24 |
Buy |
2.90 |
250 |
725 |
332,895 |
| Duey Marc | Director |
Oct 14 '24 |
Buy |
2.58 |
190 |
490 |
210,113 |
| Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr |
Oct 11 '24 |
Buy |
2.46 |
50 |
123 |
19,368 |
| Seizinger Bernd R. | Director |
Oct 11 '24 |
Buy |
2.68 |
10,000 |
26,800 |
44,730 |
| Gilad Oren | President/CEO |
Oct 14 '24 |
Buy |
2.59 |
1,000 |
2,590 |
332,645 |
| Gilad Oren | President/CEO |
Oct 10 '24 |
Buy |
2.54 |
150 |
381 |
331,645 |
| Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr |
Oct 10 '24 |
Buy |
2.61 |
450 |
1,174 |
19,318 |
0.91%
3.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):